Literature DB >> 19576252

Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis.

Andrew S Dixon1, Mudit Kakar, Korbinian M H Schneider, Jonathan E Constance, Blake C Paullin, Carol S Lim.   

Abstract

Altering the subcellular localization of signal transducing proteins is a novel approach for therapeutic intervention. Mislocalization of tumor suppressors, oncogenes, or factors involved in apoptosis results in aberrant functioning of these proteins, leading to disease. In the case of chronic myelogenous leukemia (CML), cytoplasmic Bcr-Abl causes oncogenesis/proliferation. On the other hand, nuclear entrapment of endogenous Bcr-Abl (in K562 human leukemia cells) causes apoptosis. The goal of this study was to determine whether ectopically expressed Bcr-Abl could cause apoptosis of K562 cells when specifically directed to the nucleus via strong nuclear localization signals (NLSs). A single NLS from SV40 large T-antigen or four NLSs were subcloned to Bcr-Abl (1NLS-Bcr-Abl or 4NLS-Bcr-Abl). When transfected into K562 cells, only 4NLS-Bcr-Abl translocated to the nucleus. Bcr-Abl alone was found to localize in the cell cytoplasm, colocalizing with actin due to its actin binding domain. 1NLS-Bcr-Abl also localized with actin. Apoptosis induced by 4NLS-Bcr-Abl was evaluated 24h post-transfection by morphologic determination, DNA staining, and caspase-3 assay. This is the first demonstration that altering the location of ectopically expressed Bcr-Abl can kill leukemia cells. Multiple NLSs are required to overcome Bcr-Abl binding to actin, thus driving it into the nucleus and causing apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19576252      PMCID: PMC2787801          DOI: 10.1016/j.jconrel.2009.06.026

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  31 in total

Review 1.  Cytochemical methods for the detection of apoptosis.

Authors:  M C Willingham
Journal:  J Histochem Cytochem       Date:  1999-09       Impact factor: 2.479

Review 2.  Imatinib mesylate--gold standards and silver linings.

Authors:  K Peggs
Journal:  Clin Exp Med       Date:  2004-09       Impact factor: 3.984

3.  Gleevec suppresses p63 expression in head and neck squamous cell carcinoma despite p63 activation by DNA-damaging agents.

Authors:  Weg M Ongkeko; Yi An; Theresa S Chu; Joseph Aguilera; Christopher L Dang; Jessica Wang-Rodriguez
Journal:  Laryngoscope       Date:  2006-08       Impact factor: 3.325

Review 4.  Apoptosis: the biochemistry and molecular biology of programmed cell death.

Authors:  R A Schwartzman; J A Cidlowski
Journal:  Endocr Rev       Date:  1993-04       Impact factor: 19.871

5.  BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.

Authors:  Alessandra Aloisi; Sandra Di Gregorio; Fabio Stagno; Patrizia Guglielmo; Francesca Mannino; Maria Pia Sormani; Paolo Bruzzi; Carlo Gambacorti-Passerini; Giuseppe Saglio; Salvatore Venuta; Rosario Giustolisi; Angelo Messina; Paolo Vigneri
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

6.  Crystal structure of the Aequorea victoria green fluorescent protein.

Authors:  M Ormö; A B Cubitt; K Kallio; L A Gross; R Y Tsien; S J Remington
Journal:  Science       Date:  1996-09-06       Impact factor: 47.728

7.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Authors:  Risto Kerkelä; Luanda Grazette; Rinat Yacobi; Cezar Iliescu; Richard Patten; Cara Beahm; Brian Walters; Sergei Shevtsov; Stéphanie Pesant; Fred J Clubb; Anthony Rosenzweig; Robert N Salomon; Richard A Van Etten; Joseph Alroy; Jean-Bernard Durand; Thomas Force
Journal:  Nat Med       Date:  2006-07-23       Impact factor: 53.440

8.  Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl.

Authors:  Oliver Hantschel; Silke Wiesner; Thomas Güttler; Cameron D Mackereth; Lily L Remsing Rix; Zsuzsanna Mikes; Jana Dehne; Dirk Görlich; Michael Sattler; Giulio Superti-Furga
Journal:  Mol Cell       Date:  2005-08-19       Impact factor: 17.970

9.  A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.

Authors:  J R McWhirter; D L Galasso; J Y Wang
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

10.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.

Authors:  B J Druker; S Tamura; E Buchdunger; S Ohno; G M Segal; S Fanning; J Zimmermann; N B Lydon
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

View more
  14 in total

1.  Disruption of Bcr-Abl coiled coil oligomerization by design.

Authors:  Andrew S Dixon; Scott S Pendley; Benjamin J Bruno; David W Woessner; Adrian A Shimpi; Thomas E Cheatham; Carol S Lim
Journal:  J Biol Chem       Date:  2011-06-09       Impact factor: 5.157

Review 2.  Alterations in the nucleocytoplasmic transport in apoptosis: Caspases lead the way.

Authors:  Gelina S Kopeina; Evgeniia A Prokhorova; Inna N Lavrik; Boris Zhivotovsky
Journal:  Cell Prolif       Date:  2018-06-26       Impact factor: 6.831

3.  Direct induction of apoptosis using an optimal mitochondrially targeted p53.

Authors:  Mohanad Mossalam; Karina J Matissek; Abood Okal; Jonathan E Constance; Carol S Lim
Journal:  Mol Pharm       Date:  2012-03-28       Impact factor: 4.939

4.  Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs.

Authors:  Andrew S Dixon; Jonathan E Constance; Tomoyuki Tanaka; Terence H Rabbitts; Carol S Lim
Journal:  Pharm Res       Date:  2011-12-20       Impact factor: 4.200

5.  Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis.

Authors:  Andrew S Dixon; Geoffrey D Miller; Benjamin J Bruno; Jonathan E Constance; David W Woessner; Trevor P Fidler; James C Robertson; Thomas E Cheatham; Carol S Lim
Journal:  Mol Pharm       Date:  2011-12-12       Impact factor: 4.939

Review 6.  Controlling subcellular delivery to optimize therapeutic effect.

Authors:  Mohanad Mossalam; Andrew S Dixon; Carol S Lim
Journal:  Ther Deliv       Date:  2010-07

7.  Selective targeting of c-Abl via a cryptic mitochondrial targeting signal activated by cellular redox status in leukemic and breast cancer cells.

Authors:  Jonathan E Constance; Samuel D Despres; Akemi Nishida; Carol S Lim
Journal:  Pharm Res       Date:  2012-05-02       Impact factor: 4.200

8.  Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2.

Authors:  James R Davis; Mohanad Mossalam; Carol S Lim
Journal:  Mol Pharm       Date:  2013-03-01       Impact factor: 4.939

9.  Utilizing the estrogen receptor ligand-binding domain for controlled protein translocation to the insoluble fraction.

Authors:  James R Davis; Mohanad Mossalam; Carol S Lim
Journal:  Pharm Res       Date:  2012-08-07       Impact factor: 4.200

10.  Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib.

Authors:  Jonathan E Constance; David W Woessner; Karina J Matissek; Mohanad Mossalam; Carol S Lim
Journal:  Mol Pharm       Date:  2012-10-12       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.